Schizophrenia Trial, Recruiting NCT06672588 Sponsor: Centre for Addiction and Mental Health Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06672588
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are currently admitted to a hospital or attending as an outpatient.
  • People who are able to show they can understand and agree to take part in research, as measured by a standard assessment tool.
  • People who have been diagnosed with Schizophrenia or Schizoaffective Disorder (as confirmed by a structured clinical interview) for at least 2 years.
  • People who are 18 years of age or older.
  • People whose symptoms have not responded well enough to at least 2 different antipsychotic medications taken at an adequate dose for at least 6 weeks each.
  • People whose symptoms are at least moderately severe on specific measures of psychosis, based on a standard rating scale assessment at the start of the trial.
  • People who a psychiatrist and anaesthesiologist have assessed as suitable to receive a type of brain stimulation therapy involving brief electrical or magnetic pulses.
  • People who are currently taking an antipsychotic medication at an adequate dose and are willing to keep that medication the same throughout the main treatment phase of the trial.
  • People who are able to attend and follow the trial's treatment schedule.
  • People who meet the safety requirements for the specific brain stimulation treatment used in this trial (confirm with trial site).
  • Women who could become pregnant must be willing to provide a negative pregnancy test and agree not to become pregnant during the trial.

Who may not be able to join:

  • People who have been diagnosed with a substance use disorder (not including nicotine or caffeine) within the past three months.
  • People who have a serious and unstable physical health condition alongside their mental health condition.
  • People who are pregnant or plan to become pregnant during the trial.
  • People who are assessed by the study team as likely having dementia.
  • People who have a significant neurological condition that may involve increased pressure in the brain or a growth or abnormality in the brain, such as a brain aneurysm.
  • People who have a serious medical condition that may affect their ability to safely participate (confirm with trial site for specific details).
  • People who have a metal implant inside or near the head — such as clips, shunts, stimulators, cochlear implants, or electrodes — that cannot be safely removed before the procedure.
  • People who need to take benzodiazepine medication at a dose higher than the equivalent of 2 mg of lorazepam per day, or who need to take anti-seizure medications, as these may reduce how well the treatment works.
  • People who are not able to communicate in English well enough to complete the memory and thinking tests used in the trial.
  • People who have a sensory impairment — such as significant difficulty hearing or seeing — that cannot be corrected and would prevent them from completing the thinking and memory tests.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel Blumberger, M.D., MSc., Centre for Addiction and Mental Health

Phone: 416-535-8501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre for Addiction and Mental Health
Registry
ClinicalTrials.gov
Start date
22 April 2025
Est. completion
1 November 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Brief Psychiatric Rating Scale (BPRS) Response (18-Version); MATRICS™ Consensus Cognitive Battery (MCCB)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov